Corporate Vision The polyclonal antibodies and related products made and sold by SICGEN Antibodies have already been used successfully across a host of life sciences research areas, including against the likes of fluorescent proteins such as GFP, mCherry, and tdTomato. Having drawn the attention of fellow industry professionals working in this space, these offerings have also been featured in a number of leading life sciences publications, with Nature, Cell, and Science being just some of the examples. Whilst its team appreciate the acclaim, at the heart of SICGEN remains a steadfast drive to offer products and services that are of the highest quality, all whilst keeping prices competitive and customers satisfied. As of this year, this best-in-class product line has expanded to more than 300 separate items, with some of the research focus areas that have been hit thanks to it including western blotting, or WB, (a technique to detect certain proteins in tissue samples) and immunofluorescence, or IF, (a light microscope technique). This is just the beginning, as SICGEN is continuing to develop new products and services on the back of these antibodies that can appease its discerning customer base, which consists primarily of leading educational and research institutions, pharmaceutical manufacturers, and biotechnology distributors. Operating on a worldwide scale, the company’s primary markets are North America, Europe, and the Far East. A suite of marketing methods see these target markets reached effectively, with a particular focus placed on e-catalogues. North America suffers from no shortage of antibody-producing companies, but SICGEN’s native Europe sees far fewer companies manufacturing high-quality antibodies by comparison. Having targeted this niche market, as well as additional specific niches within it such as WB and IF, this is a company leading its field. Moreover, since all of its antibodies are raised in goats – animals which have a higher capacity for antiserum production and are both affinity-purified and highly concentrated – their quality is second to none. Beyond this, Dr Ramalho is quick to praise the skill of his hardworking and resilient team, which is comprised of a small number of individuals whose dedication and focus to both the present and future of this industry is a sight to behold. This excellent team has resulted in the company successfully traversing the ever-changing antibody landscape over the past 15 years, a period which has seen large companies come in and try to take over. Despite being small in size, SICGEN more than makes up for it by being flexible and adaptable. A fitting example of this can be found in the company’s strategic plan, which sees it strive to expand the number of antibodies it offers whilst simultaneously unveiling additional uses for its existing ones. Another cornerstone of this plan includes working with modified antibodies tagged with fluorescent modules, meaning that they act as a sort of catalyst for experiments. Antibodies of this variety are highly sought after, and investing Since 2009, Europe’s SICGEN Antibodies has been excelling in the field of polyclonal antibodies for use in cell biology research – developing, manufacturing, and marketing these collections of immunoglobulin molecules that offer up a host of benefits for its research-driven customers. Founded under the NEOTEC Initiative by CEO Dr José Ramalho, a Portuguese scientist, as well as two other industry-leading individuals, SICGEN remains committed to becoming a global polyclonal antibody producer. Polyclonal Antibody Manufacturers of the Year 2024 in them will only further the company’s appeal to the scientific community’s evolving needs. It is as a result of these industry-wide shifts that SICGEN places such great emphasis on its research and development efforts, as stagnation is one of the worst things that can be befall a company operating in this environment. This is why, across its R&D initiatives, SICGEN’s product team will design and assess the viability of a new antibody creation, before deciding whether or not it is worthy of release. It is important to tread carefully however, as a new offering can either fill a gap in the market or cost the business a fortune. The importance of being careful with money is something that SICGEN recognised from day one, given that it first began to sell its antibodies during the global financial crisis that was taking place at the time. Overcoming the odds is thus something that has defined SICGEN Antibodies’ journey so far, and with its antibodies having been featured across hundreds of prestigious scientific journals, this is a company that is continuing to have a massive impact on the exciting future of polyclonal antibodies. Contact Details Contact: Dr José Ramalho Company: SICGEN Antibodies Web Address: https://sicgen.pt/
RkJQdWJsaXNoZXIy MTUyMDQwMA==